Karlton Spindle, inventor of the patented and FDA 510 (k)-cleared NavJam "smart" Jamshidi, co-invented the FDA De Novo--approved RJB (TM) intraoperative measurement device at Ruthless Spine. He said ...

Translumbosacral neuromodulation therapy shows potential in improving neuropathic dysfunction and reducing symptoms in patients with fecal incontinence.

ABSTRACT: Background: The management of myelomeningocele (MMC) defects poses significant reconstructive challenges. Numerous methods of reconstruction have been described. Nevertheless, the choice of ...

Abstract: Clinical research indicates that the epidural spinal cord stimulation (ESCS) at lumbosacral segment has shown potential for promoting locomotor recovery in patients with incomplete spinal ...

From a study at the New York Orthopedic Hospital. Read before the Vermont State Medical Society at its Annual Meeting held in Burlington, Vermont, October 4 and 5, 1934. Bellerose, Maurice N. — ...

Lumbosacral radicular pain, often referred to as sciatica, is a type of pain that arises from irritation or inflammation of a low back spinal nerve. People typically experience pain radiating down the ...

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of ...

Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from its Phase 2 study of suzetrigine in people with painful ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...

“Suzetrigine has again demonstrated its potential to fill an important unmet need in the treatment of pain. Today's LSR results are consistent with previous studies of this pain signal inhibitor in ...